FDA grants priority review for sBLA of Tecentriq in NSCLC -EFGR -ALK PD-L1.- Roche
Related news and insights
EQRx, Inc. a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase III studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.
Regeneron Pharmaceuticals, Inc. announced that the FDA has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC).
BeiGene has announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).